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Abstract: As the population ages, there is a growing need for effective therapies for the treatment 
of neurological diseases. A limited number of therapeutics are currently available to improve 
cognitive function and research is limited by the need for in vivo models. Zebraﬁ  sh have recently 
become a focus of neurobehavioral studies since larvae display neuropathological and behavioral 
phenotypes that are quantiﬁ  able and relate to those seen in man. Due to the small size of Zebraﬁ  sh 
larvae, assays can be undertaken in 96 well plates and as the larvae can live in as little as 200 µl 
of ﬂ  uid, only a few milligrams of compound are needed for screening. Thus in vivo analysis of 
the effects of compounds can be undertaken at much earlier stages in the drug discovery process. 
This review will look at the utility of the zebraﬁ  sh in the study of neurological diseases and its 
role in improving the throughput of candidate compounds in in vivo screens.
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Introduction
Cognitive impairment manifests itself in a number of neurological diseases such as 
schizophrenia, Huntington’s, Parkinson’s, and Alzheimer’s diseases. As the general 
population ages, there will be an increased incidence of these disease and disorders and 
thus a growing need for effective therapies for the treatment of the associated cognitive 
deﬁ  cits. A limited number of therapeutics are currently available to improve cognitive 
function and research is limited by the need for predictive in vivo models.
Introduction to zebraﬁ  sh
Zebraﬁ  sh have recently become a focus of neurobehavioral studies since larvae display 
learning, sleep, drug addiction, and other neurobehavioral phenotypes that are quantiﬁ  able 
and relate to those seen in man (Zhdanova et al 2001; Cahill 2002; Guo 2004; Orger et al 
2004; Ninkovic et al 2006). Furthermore, the organization of the zebraﬁ  sh genome and the 
genetic pathways controlling signal transduction and development are highly conserved 
between zebraﬁ  sh and man (Postlethwait et al 2000). At seven days post fertilization (d.p.f.) 
the larvae are approximately 4 mm long. Due to this small size of the larvae, assays can 
be undertaken in 96 well plates and as the larvae can live in as little as 200 µl of ﬂ  uid; 
only a few milligrams of compound are needed for screening. Thus in vivo analysis of 
the effects of compounds can be undertaken at much earlier stages in the drug discovery 
process than has previously been possible, which is facilitated by the fact that zebraﬁ  sh 
are dimethyl sulfoxide (DMSO) tolerant and readily absorb compounds from the water. 
The relative ease of maintaining large stocks of ﬁ  sh and its high fecundity can provide the 
investigator with large numbers of larvae to analyze. The above properties have established 
the zebraﬁ  sh as an excellent model system that is relevant to studies of human diseases 
(Grunwald and Eisen 2002). Conventional drug discovery has recently employed system-
atic, target-based high throughput screening in puriﬁ  ed proteins or cells as primary screens 
with in vivo models as tertiary screens in the cascade after more mechanistic cell assays. Neuropsychiatric Disease and Treatment 2008:4(3) 568
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While the in vitro screens have been successful at identifying 
small molecules affecting known mechanisms, there is still the 
need to identify modulators of complex in vivo phenotypes in 
the whole organism for less well understood pathways or those 
that only occur in a physiological/pathophysiological context. 
The advantages of using larval zebraﬁ  sh described above allow 
higher throughput in vivo screening for phenotypic endpoints, 
and the utility of zebraﬁ  sh in small molecule screening has 
been the subject of several reviews (MacRae and Peterson 
2003; Zon and Peterson 2005; Murphey and Zon 2006; Berger 
and Currie 2007). However, there are disadvantages to this 
approach. Namely, that uptake of compound into the zebraﬁ  sh 
can be variable and should be measured for accurate interpreta-
tion of results (Berghmans et al 2008) and particularly to avoid 
false negatives, and the larval stage of the zebraﬁ  sh may not be 
appropriate in all disease areas.
In a comparison of the zebraﬁ  sh brain structure with man, 
there are some differences between teleosts and mammals. 
Notably, ﬁ  sh have smaller cerebral hemispheres and there are 
differences in the layout of the forebrain (extensively reviewed 
by Wullimann and Mueller 2004) and the structure and func-
tion of the optic tectum (Luque et al 2005). However, the 
overall organisation of the zebraﬁ  sh brain is similar to other 
vertebrates, having similarly deﬁ  ned areas such the hypothala-
mus and olfactory bulb, encompassing structures of the lateral 
pallium, which appear to be homologous to the mammalian 
hippocampus (Tropepe and Sive 2003). In addition, the main 
neurotransmitter systems such as the cholinergic, dopaminergic, 
and noradrenergic pathways are present and have been mapped 
throughout the brain (Rink and Wullimann 2004; Wullimann 
and Mueller 2004). Zebraﬁ  sh have a developmentally regulated 
blood-brain barrier. Functional analysis using ﬂ  uorescent dyes 
and anatomical analysis by transmission electron microscopy 
provides evidence that the zebraﬁ  sh blood brain barrier is func-
tional at 10 d.p.f. (Goldsmith and Fleming 2007). Additionally, 
it was also shown that zebraﬁ  sh paralogues of P-glycoprotein 
(Pgp) are ﬁ  rst detected in the vasculature endothelium of the 
central nervous system (CNS) at 8 d.p.f., which coincides with 
the efﬂ  ux of the Pgp substrate, rhodamine 123 from the zebraf-
ish brain. These data suggest that the zebraﬁ  sh is a relevant 
model for the study of neurological diseases.
Zebraﬁ  sh neurodegenerative 
disease models
Huntington’s disease
Huntington’s disease (HD) is a monogenic polyglutamine 
(polyQ) neurodegenerative disorder which results in cognitive 
deﬁ  cits in attentional and executive functions along with 
defects in visual working memory (Montoya et al 2006). 
Neurodegeneration occurs primarily in the striatal medium-
sized spiny neurons which project to the substantia nigra and 
globus pallidus. HD has a prevalence of approximately 5 in 
100,000 worldwide, the median age of onset being 39 (Cowan 
and Raymond 2006). In zebraﬁ  sh, the huntingtin (Htt) gene 
has been cloned and sequenced with a 3121 predicted amino 
acid protein, which has 70% identity with the human peptide 
sequence (Karlovich et al 1998). Knockdown of Htt using mor-
pholino technology disrupted a number of features of zebraﬁ  sh 
development resulting in small head and eyes, delayed or paler 
pigmentation and colorless hypochromic blood (Lumsden et al 
2007). In a separate study, a ‘Huntington’s like’ zebraﬁ  sh was 
created by inserting mRNA of the N-terminal fragment of Htt 
with different length polyQ repeats linked to a GFP-fusion 
protein (Schiffer et al 2007). The increasing polyQ length was 
associated with an increase in abnormalities and apoptosis in 
the embryos as early as 24 hours p.f. The embryos containing 
the Q102-GFP developed inclusions in the cytoplasm, which 
increased in size by incorporation of the soluble Q102 peptide 
leading to insoluble deposits. These ﬁ  ndings conﬁ  rmed a previ-
ous study where expression of poly Q56 or greater exhibited 
toxicity and abnormalities in the zebraﬁ  sh embryos with inclu-
sion bodies formed in more than 70% of embryos (Miller et al 
2005). These studies also investigated the effect of aggregation 
inhibitors which suggested that the prevention of aggregation 
did not reduce the toxic effect on the ﬁ  sh, implying that the 
formation of smaller intermediate aggregates were the main 
cause of toxicity. Thus, these models could be used to screen for 
novel compounds for the treatment of HD by evaluating either 
the prevention of aggregate formation, enhanced clearance of 
aggregates or the reduction in embryo death.
Alzheimer’s disease
Alzheimer’s disease (AD) is the most common cause of 
dementia, with nearly 50% of dementia cases worldwide being 
attributed to AD. The prevalence increases from 1.53% of the 
population between 65–69 years to as high as 30% between 
80–85 years (Vandenberghe and Tournoy 2005; Mount and 
Downton 2006). AD is characterized histopathologically 
by amyloid-beta (Aβ) containing plaques and intracellular 
neuroﬁ  brillary tangles consisting of abnormally phosphory-
lated tau protein in the brain (Selkoe 2000; Mudher and 
Lovestone 2002). Cognitive impairments manifest themselves 
as progressive episodic memory loss and effects on executive 
functions, which are usually accompanied by mini-mental state 
examination scores below 24 (Vandenberghe and Tournoy 
2005). Zebraﬁ  sh possess two homologues of amyloid precursor Neuropsychiatric Disease and Treatment 2008:4(3) 569
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protein (APP) with good (about 70%) homology to human APP 
(Musa et al 2001). Studies have demonstrated the presence of 
the functional γ-secretase machinery to produce Aβ in zebraf-
ish (for a full review see Newman et al 2007). Other studies 
have investigated the tau protein in zebraﬁ  sh (Tomasiewicz 
et al 2002). Microinjection of four repeat human tau GFP 
constructs into 1–2 cell stage embryos showed disruption to 
the cytoskeletal structure and tau trafﬁ  cking by 48 hours post 
injection. This eventually led to hyperphosphorylated ﬁ  brillar 
tau staining similar to that seen with neuroﬁ  brillary tangles in 
pathology of AD patients. These models offer the ability to 
screen for novel therapeutics that that decrease Aβ load and 
decrease the hyperphosphorylation seen in tauopathies.
Parkinson’s disease
Although predominantly a movement disorder, there are a 
number of cognitive impairments associated with Parkinson’s 
disease (PD) (Galvin 2006). These include executive dys-
function and impaired memory retrieval and the prevalence 
increases from 2.7% per year at 55–64 years to 13.7% at 
70–79 years. Parkinson’s disease is characterized neuropatho-
logically by degeneration of dopaminergic neurons and the 
appearance of intracytoplasmic inclusions called Lewy bod-
ies. Genetically, six genes linked to Parkinsonism have been 
identiﬁ  ed: Parkin, DJ-1, PINK1, α-Synuclein, UCHL-1, and 
LRRK2 (Abeliovich and Beal 2006). Of these genes two have 
been studied in zebraﬁ  sh with preliminary work beginning on 
the others (Paquet et al 2006; Shankaran et al 2006).
Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) was 
originally identiﬁ  ed in siblings with a strong family history 
of PD (Leroy et al 1998). In zebraﬁ  sh, UCH-L1 mRNA 
was expressed in neuronal cells at 1 d.p.f. (Son et al 2003). 
UCH-L1 was detected in the diencephalon and ventral 
region of the mid and hindbrain, which are associated with 
motoneuron development (although which mammalian 
motoneurons these were correlated with was not investigated). 
Interestingly, in the ventral diencephalon, an area functionally 
homologous to the substantia nigra in humans, the UCH -L1 
was co-expressed with tyrosine hydroxylase substantiating the 
association of UCH -L1 with dopaminergic neurons.
Patients with autosomal recessively inherited DJ-1 
mutations typically present with early onset PD. In embryonic 
and adult zebraﬁ  sh DJ-1 is expressed throughout the body 
with higher abundance in the brain, eyes, heart and muscle 
of the adult (Bretaud et al 2007). The zebraﬁ  sh DJ-1 protein 
has high homology with human (83%) and mouse DJ-1 
(80%). Knockdown of DJ-1 in the zebraﬁ  sh did not affect the 
number of dopaminergic neurons in a similar manner to the 
mouse DJ-1 null mutant (Chen et al 2005). In keeping with 
the suggested role of DJ-1, the knockdown zebraﬁ  sh embryos 
were more susceptible to oxidative stress and had signiﬁ  cantly 
elevated SOD1 levels. Furthermore, simultaneous knockdown 
of DJ-1 and p53 caused dopaminergic neuronal loss 
demonstrating a strong interaction between these genes.
The main pharmacological approach to studying PD in 
animal models has been using 1-methythl-4-phenyl-1, 2, 
3, 6-tetrahydropyridine (MPTP) which reproduces some of 
the effects of idiopathic Parkinson’s disease (Smeyne and 
Jackson-Lewis 2005). Zebraﬁ  sh embryos treated with MPTP 
demonstrated a loss of TH and DAT- expressing neurons which 
could be rescued using the monoamine oxidase-B inhibitor 
deprenyl (Bretaud et al 2004; Lam et al 2005; McKinley et al 
2005). A reduction was also seen in the locomotor activity 
mimicking motor effects seen in PD patients; however this did 
not always occur simultaneously with the reduction in dopami-
nergic cells (Salzmann et al 2006) and in the adult a reduction 
is seen in the locomotor activity without an effect being seen 
in dopaminergic cells (Anichtchik et al 2004). The utility of 
these various models will aid screening for novel compounds 
for both the hereditary and the idiopathic forms of PD.
Schizophrenia
Schizophrenia affects approximately 1% of the world’s popula-
tion and is characterized by neuronal dysfunction resulting in 
deﬁ  cits in a number of different cognitive areas such as visual 
and verbal memory and learning and attention (Nuechterlein 
et al 2004; Tamminga 2006). Patients with schizophrenia and 
other conditions including Huntington’s disease have been 
shown to exhibit impaired prepulse inhibition (PPI) (Swerdlow 
et al 1995; Braff et al 2001). PPI is a neurological phenom-
enon in which a weak prestimulus or prepulse suppresses 
the response to a subsequent startling stimulus and is highly 
conserved among vertebrates. A recent study of sensorimotor 
gating in zebraﬁ  sh described an assay for PPI in 6 d.p.f. larvae 
(Burgess and Granato 2007). In this study, the effective inter-
stimulus interval for inhibition along with the dopaminergic 
and glutamergic modulation of PPI was found to be comparable 
to that in mammals. Again, using this paradigm will allow the 
screening of novel therapeutics for schizophrenia at an earlier 
stage of the drug discovery process.
Assays for assessing learning 
and memory in zebraﬁ  sh
Mild cognitive impairment, a risk factor for AD, consists of a 
number of etiologies and is characterized by a slight impairment 
(usually memory) in cognitive function of everyday activities Neuropsychiatric Disease and Treatment 2008:4(3) 570
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(Levey et al 2006). Its prevalence in epidemiological studies 
ranges from 3%–19% in adults over 65 years old, with half of 
adults diagnosed with MCI progressing to dementia (Gauthier 
et al 2006). There have been a number of models developed 
to facilitate the study of learning and memory in zebraﬁ  sh. 
Nonassociative learning has been studied in larval zebraﬁ  sh 
by monitoring the reduction in a startle response to a series 
of acoustic stimuli (Best et al 2007). This habituation to the 
stimuli was modulated by current therapies for improving 
cognitive ability in Alzheimer’s disease patients, namely 
donepezil and memantine, as well as by the phosphodiesterase 
(PDE) 4 inhibitor rolipram, a compound shown to increase 
learning and memory in rodent studies. Associative learning 
has been demonstrated by visual discrimination in a T maze 
with food reward linked to certain colours (Colwill et al 
2005). The adult zebraﬁ  sh learned to associate one of a 
pair of colours with food and reversal and extinction were 
also shown in this system. A T maze has also been used to 
determine the roles of glutamergic transmission (Swain et al 
2004) and histamine in learning and memory in adult zebraﬁ  sh 
(Peitsaro et al 2003). Furthermore, adult zebraﬁ  sh have been 
shown to display quick and reliable learning by swimming 
to certain locations within a tank to avoid adverse stimulus, 
such as a moving net (Arthur and Levin 2001) or electrical 
shocks (Xu et al 2007) and show cognitive ﬂ  exibility in that 
they show reversal when the contingencies are changed over. 
Active avoidance to avoid mild electrical shocks was used in 
a similar experimental paradigm to demonstrate the possible 
involvement of cell adhesion molecule L1.1 in memory 
consolidation (Pradel et al 2000). A three compartment maze 
with a central chamber and a choice of moving to the left or 
right chambers has been used to demonstrate spatial and non 
spatial visual discrimination learning (Arthur and Levin 2001) 
and to demonstrate the improvement in learning in response 
to nicotine treatment (Levin et al 2006a) in adult zebraﬁ  sh. A 
spatial alternation paradigm has been used to show that adult 
zebraﬁ  sh learn to alternate between ends of the test tank for 
food reward, rapidly achieving high correct response levels 
(Williams et al 2002). This behavior is recalled if the zebraﬁ  sh 
are tested again after 10 days. This type of learning can be 
impaired in zebraﬁ  sh treated with ethanol (10 mM) or lead (10 
µM) for the ﬁ  rst 24 hours post fertilization of development as 
they demonstrated signiﬁ  cant learning and memory deﬁ  cits 
when treated in the three compartment maze assay (Carvan 
et al 2004). The progress in the area of learning and memory 
experimental paradigms in zebraﬁ  sh suggest the possible 
utility of this model organism in behavioral pharmacology 
studies.
Pharmacology mediating cognition
One of the key challenges with CNS drug discovery is the 
need to isolate speciﬁ  c areas of the brain mediating a particu-
lar disorder or disease. Therapies have become available for 
cognitive impairment, although these have been dominated 
by two classes of drug, acetylcholinesterase inhibitors and 
N-methyl-D-aspartate (NMDA) antagonists exempliﬁ  ed by 
donepezil and memantine, respectively. Since a number of 
publications and reviews have covered these therapies, the 
pathways they mediate and their effects in both preclinical 
models (Levin and Simon 1998; Levin et al 2006b; Cosman 
et al 2007) and clinical trials (Burns et al 1999; Birks 2006; 
Geerts and Grossberg 2006; Ringman and Cummings 2006; 
Robinson and Keating 2006), as well as the effects of these 
pathways on zebraﬁ  sh behavior (Levin and Chen 2004; Nam 
et al 2004; Levin et al 2006a; McDearmid and Drapeau 2006), 
the latter part of this review will concentrate on four other 
interesting targets; these being phosphodiesterases, histamine 
H3 receptors, 5HT6 receptors, and AMPAkines, which are 
currently being investigated preclinically and the utility of 
zebraﬁ  sh to aid in the characterization of these targets.
Phosphodiesterase inhibitors
The role of phosphodiesterases in cognition have been well 
documented (for reviews see Rose et al 2005; Hebb and 
Robertson 2007). Currently, in mammals there are 11 distinct 
families encoding 21 genes. Of these, PDE 1, 2, 4, and 10 
are primarily located in the mammalian brain. PDE1B and 
PDE10 are located in the striatum and expression levels of 
both were found to decline in the HD mouse models R6/1 
and R6/2, suggesting a role for these PDEs in the deﬁ  cits 
associated with HD (Hebb et al 2004). The PDE 4 A, B, and 
C isoforms are distributed throughout regions of the brain, 
with PDE4A and 4D observed in the hippocampus along with 
4D, and all three isoforms were seen to different extents in 
the cortical regions (Cherry and Davis 1999). Furthermore, 
although the levels of PDE4A were low in the substantia 
nigra there was no change in levels between the control and 
HD mice (Hebb et al 2004). Since the levels of PDE4s may 
not change in Huntington’s disease it may provide a viable 
target for the associated cognitive deﬁ  cits.
Treatment of rodents with rolipram, a nonselective PDE4 
inhibitor, demonstrated either enhancement of memory 
and long term potentiation or a reversal of pharmacologi-
cally induced memory deﬁ  cit (Imanishi et al 1997; Barad 
et al 1998; Zhang et al 2000; Zhang and O’Donnell 2000). 
Other studies with the PDE5 inhibitor sildenaﬁ  l, also dem-
onstrated cognitive improvement in the object recognition Neuropsychiatric Disease and Treatment 2008:4(3) 571
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and attenuated the scopolamine induced learning deﬁ  cit in 
mice suggesting this family as a possible therapeutic target 
(Prickaerts et al 2002; Devan et al 2004). Futhermore, more 
recent studies have investigated PDE10A as a therapeutic 
target for treating schizophrenia and HD (Hebb et al 2004; 
Siuciak et al 2006). However, despite the substantial data 
to support the role of PDEs in learning and memory, so 
far only the only reported studies for the clinical use of 
phosphodiesterase inhibitors, has been in the treatment of 
depression using rolipram (reviewed by Zhu et al 2001; 
Renau 2004).
In zebraﬁ  sh, 2’,3’-cyclic-nucleotide 3’- phosphodiesterase 
was first reported as being induced in an optic nerve 
regeneration study (Ballestero et al 1999). Further searches 
of the National Center for Biotechnology Information 
(NCBI) protein sequence ﬁ  nder revealed zebraﬁ  sh possess 
proteins with similarity to the phosphodiesterases 1, 
3–7, 9–11. Two enzymes of primary interest are the PDE4 
(http://www.ncbi.nlm.nih.gov/BLAST, accession number: 
CAK10806), with an identity to the human PDE4C1 
of 63%, rat 4D 67% and mouse 4C 61%, and PDE10A 
(http://www.ncbi.nlm.nih.gov/BLAST, accession number: 
NP 957396), which has an identity with the human, rat, 
and mouse PDE10A of 83% (for summary see Table 1). 
Speciﬁ  c orthologues of the other splice forms may also exist 
but have yet to be reported. As yet, little has been reported 
in zebraﬁ  sh as to the effects of PDE inhibitors on learning 
and memory; though this lab has reported that rolipram 
enhances the acoustic startle response in 7 d.p.f. larval 
zebraﬁ  sh and delays habituation to consecutives tones (Best 
et al 2007). These effects in zebraﬁ  sh are similar to those 
seen in previous rat studies (Kehne et al 1991), suggesting 
the presence of functional phosphodiesterase 4 enzymes 
or at the very least high-afﬁ  nity rolipram binding sites. 
Clearly more investigations are needed to elucidate the 
distribution of PDEs in ﬁ  sh and their role in ﬁ  sh behavior 
and cognition.
Histamine 3 receptor antagonists
The histamine 3 (H3) receptor is a G protein coupled receptor 
identiﬁ  ed in the 1980s and pursued as a drug target for a 
number of indications (for reviews see Witkin and Nelson 
2004; Esbenshade et al 2006; Bonaventure et al 2007). 
H3 receptors are centrally located with mRNA distributed 
in regions connected to memory and learning, such as 
the hippocampus and cortex (Lovenberg et al 1999). In 
recombinant receptor systems H3 receptors have been shown 
to have constitutive activity (reviewed by Arrang et al 2007) 
and research has centred on investigating inverse agonists/
antagonists for cognitive disorders. Thioperamide has been 
used to examine the effect of H3 receptor antagonists on 
learning and memory and clobenpropit has been shown to 
reverse scopolamine-induced learning deﬁ  cits as well as 
increasing social memory, attention and inhibitory avoidance. 
However, thioperamide and clobenpropit impair fear 
conditioning suggesting H3 antagonists may be speciﬁ  c in 
their role in mediating cognition (Passani et al 2004; Witkin 
and Nelson 2004; Esbenshade et al 2006; Bonaventure et al 
2007). A number of pharmaceutical companies have programs 
based around H3 antagonists with clinical candidates reported 
in Phase I (see Esbenshade et al 2006).
Three histamine receptors H1, H2, and H3 have been 
cloned and expressed in zebraﬁ  sh (Peitsaro et al 2007). 
When compared with the distribution in mammalian brain, 
the histaminergic neurons are more tightly located around 
the posterior recess and are more ventral to the mammillary 
body than in rodents. However, the rostrocaudal distribution 
is very similar to that seen in the rat and overall the projec-
tions patterns are highly conserved (Kaslin and Panula 2001). 
Comparison of the H3 receptor peptide sequence showed 
50% identity with the human (see Table 1) (Peitsaro et al 
2007), and binding studies demonstrated the H3 receptor was 
expressed throughout the zebraﬁ  sh brain with the greatest 
intensity in the optic tectum and hypothalamus (Peitsaro 
et al 2000). Zebraﬁ  sh at 5 d.p.f. treated with thioperamide 
(100 µM) demonstrated a decrease in locomotor activity 
although no toxicity assessment was given to determine 
whether this decrease was an effect was speciﬁ  c antagonism 
or a reduction due to generalised toxicity. Other studies in 
goldﬁ  sh have demonstrated involvement of H1 and H2 in 
inhibitory avoidance (Coﬁ  el and Mattioli 2006).
5HT6 receptor antagonists
5-Hydoxytryptamine (5-HT) receptors so far are composed 
of seven different subtypes which have been implicated in 
mediating cognition (Meneses 1999, 2007). They are all 
Table 1 Homology of the rat and zebraﬁ  sh with the human receptors 
which have been associated with learning and memory
Human receptor  Rat  Zebraﬁ  sh
PDE 4  71%  63%
PDE 10  95%  83%
H3 91%  50%
5HT6 89%  54%
GluR1 97%  71%
GluR2 98%  87%
GluR3 98%  88%
GluR4 99%  88%Neuropsychiatric Disease and Treatment 2008:4(3) 572
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found in areas of the brain connected with learning and 
memory, but attention has focussed on 5-HT6, which appears 
to have a greater role in long-term memory (for review see 
Mitchell and Neumaier 2005). A number of antagonists 
(eg, RO4368554, SB-271046) have been shown to reverse 
scopolamine-induced deﬁ  cits in passive avoidance assays in 
rats as well as enhancing object recognition (Foley et al 2004; 
Mitchell and Neumaier 2005; Hirst et al 2006; Schreiber et al 
2007), although the consistency of the effect at this target has 
been disputed, which raises questions as to brain penetrance 
and selectivity of the various compounds used (Russell and 
Dias 2002). Again, despite the literature supporting their 
effect in learning and memory, there are currently no reports 
of clinical trials for 5HT6 antagonists.
In zebraﬁ  sh, 5-HT neurons are expressed in the spinal 
cord as early as 1 d.pf. with populations in the telencephalon, 
hindbrain and throughout the brain by 5 d.p.f. (Drapeau et al 
2002; McLean and Fetcho 2004). In the adult these neurons 
cluster in the area of the hypothalamus and habenula (Kaslin 
and Panula 2001). A search of the NCBI protein sequence 
ﬁ  nder database and blast search shows that zebraﬁ  sh have 
at least three recognised 5-HT receptors namely 1, 2 and 7 
(http://www.ncbi.nlm.nih.gov/BLAST). This has been con-
ﬁ  rmed with studies using methysergide a 5-HT1,2,7 antago-
nist which modulated locomotor activity in larval zebraﬁ  sh 
(Drapeau et al 2002; Brustein and Drapeau 2005). Studies in 
goldﬁ  sh have demonstrated the presence of 5-HT1A in the 
retina (Schmeer et al 2001). Interestingly, a blast search using 
the human 5-HT6 peptide sequence revealed 54% identity 
with a hypothetical protein (accession number: XP 696681) 
which also has 52% and 50% identity with the rat and mouse 
5-HT6 sequences respectively (see Table 1).
AMPA receptor potentiators
Alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic 
acid (AMPA) receptors are glutamate receptors comprising 
four different subunits GluRA1-A4, are found throughout 
the CNS mediating fast excitatory transmission (for a com-
prehensive review see O’Neill et al 2004). Early studies 
have shown the presence of multiple AMPA receptors in the 
CA1/CA2 region of the hippocampus suggesting this as a 
target for cognition (Wenthold et al 1996). Ampakines are a 
diverse class of compounds which positively modulate gluta-
materic AMPA receptors with pyrrolidones (eg, piracetam) 
and piperidines (CX516) being examples (see O’Neill et al 
2004; O’Neill and Dix 2007). These compounds have been 
studied in a number of different rodent memory tasks such as 
spatial memory, delayed-nonmatch-to sample and extinction 
learning and have been shown to improve performance 
(Staubli et al 1994; Hampson et al 1998; Zushida et al 2007). 
However, despite some early encouraging data (Lynch and 
Gall 2006), recent clinical results have been mixed with the 
ampakine farampator increasing short-term memory trial of 
the symbol digit recall test in elderly patients (Wezenberg 
et al 2007) whereas CX516 used as an add-on therapy did not 
alter the composite cognitive score compared to the placebo 
group in schizophrenic patients (Goff et al 2007) or improve 
cognitive outcomes in patients with fragile X syndrome 
(Berry-Kravis et al 2006) suggesting these compounds may 
not have been dosed adequately or that they need to be used 
more selectively for cognitive impairments.
Zebraﬁ  sh possess the AMPA receptors subunits GluR1-4 
with each one consisting of a subtype A and B (NCBI protein 
database; http://www.ncbi.nlm.nih.gov/sites/entrez). A blast 
search between the subtypes shows a similarity between the 
A and B subtypes ranges from 82% for GluR1, 88% GluR3 
to 92% for GluR2 and 4. Compared with human, rat, and 
mouse, the zebraﬁ  sh receptors have very good identity, the 
1A subtype has 71% identity with the human, rat, and mouse 
GluR1 sequences. The GluR2-4A receptors have higher 
identities with human, rat and mouse of between 85%–90% 
with the equivalent protein sequence (see Table 1). AMPA 
receptors have been found and studied in the retina, hindbrain, 
spinal cord, and Mauthner neurons of zebraﬁ  sh (Ali et al 2000; 
Yazulla and Studholme 2001; Patten and Ali 2007). They are 
also associated with the neuromuscular junction in zebraﬁ  sh 
(Todd et al 2004). Not much has been reported in the zebraﬁ  sh 
literature as to the affect of AMPAkines on their learning and 
memory; however studies on nonassociative learning in this 
lab investigating piracetam have found that it increased the 
ASR and prolonged the habituation (unpublished data) similar 
to the other cognition enhancers tested.
Conclusion
It is now recognised that zebraﬁ  sh possess a great deal of 
similarity to mammals and are an extremely useful model 
for screening compounds at several stages of the drug 
discovery process (see Figure 1). As more is reported 
on the efﬁ  cacy models in zebraﬁ  sh its utility as an early 
stage screening tool for the discovery of CNS therapeutics 
should enable increased throughput of in vivo analysis 
of novel compounds for neurological disorders. In this 
review we have described the application of the zebraﬁ  sh 
models to neurodegenerative disorders, schizophrenia and 
learning and memory. Several of these diseases affect an 
aging population and are adult onset raising questions as Neuropsychiatric Disease and Treatment 2008:4(3) 573
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to the appropriateness of using a rapidly developing larval 
system. However, early phenotypes are observable and 
in comparison with rodents the zebraﬁ  sh larvae are not 
foetal but are closer to juveniles in that the nervous system 
is mature, organs are functioning and tissue architecture 
is fully developed by the time at which many of the assays 
are performed. In this review we have also described four 
validated pharmacological targets which are being inves-
tigated preclinically for impaired learning and memory; 
phosphodiesterases, histamine 3, 5HT-6 and AMPA, and 
have illustrated how zebraﬁ  sh may be used in the assess-
ment of these targets. As more information is reported on 
neurological assays in zebraﬁ  sh, the utility of this model 
organism as an early stage screening tool for CNS disorders 
should help increase in vivo throughput and ameliorate the 
cost associated with drug screening in mammals.
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